Research programme: acromegaly therapeutics - Ipsen Bioinnovation

Drug Profile

Research programme: acromegaly therapeutics - Ipsen Bioinnovation

Alternative Names: SXN 101959

Latest Information Update: 17 Jul 2015

Price : $50

At a glance

  • Originator Syntaxin
  • Developer Ipsen Bioinnovation
  • Class Bacterial toxins; Botulinum toxins; Recombinant proteins
  • Mechanism of Action Growth hormone releasing factor agonists; Pituitary hormone inhibitors; SNARE protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acromegaly

Most Recent Events

  • 24 Jul 2013 SXN 101959 is still in preclinical development for Acromegaly in the United Kingdom
  • 15 Jul 2013 Ipsen acquires Syntaxin
  • 31 Jul 2009 Preclinical trials in Acromegaly in the United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top